Discovery of PTN as a serum-based biomarker of pro-metastatic prostate cancer

Distinguishing clinically significant from indolent prostate cancer (PC) is a major clinical challenge. We utilised targeted protein biomarker discovery approach to identify biomarkers specific for pro-metastatic PC. Serum samples from the cancer-free group; Cambridge Prognostic Group 1 (CPG1, low r...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Shiqin, Shen, Michelle, Hsu, En-Chi, Zhang, Chiyuan Amy, Garcia-Marques, Fernando, Nolley, Rosalie, Koul, Kashyap, Rice, Meghan A., Aslan, Merve, Pitteri, Sharon J., Massie, Charlie, George, Anne, Brooks, James D., Gnanapragasam, Vincent J., Stoyanova, Tanya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7921397/
https://www.ncbi.nlm.nih.gov/pubmed/33288843
http://dx.doi.org/10.1038/s41416-020-01200-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7921397/
https://www.ncbi.nlm.nih.gov/pubmed/33288843
http://dx.doi.org/10.1038/s41416-020-01200-0

Ejemplares similares